Granted Patent
B2
US 12,465,578 · App. 18/695,071 · Granted Nov 11, 2025
Substituted alpha-ethyl phenylalkylamines
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are phenylalkylamines, such as 2,5-disubstituted and 2,4,5-trisubstituted phenylalkylamines. In some embodiments, the phenylalkylamines are asymmetrically substituted. In some embodiments, such compounds modulate the activity of monoamine receptors and/or monoamine transporters. Also provided are methods for the preparation of phenylalkylamines and pharmaceutical compositions thereof. Methods of using the phenylalkylamines, alone or in combination with other therapeutic agents, are provided. In some embodiments, phenylalkylamines are used to treat CNS disorders, such as mental health conditions and neurodegenerative disorders, or are used for the improvement of mental health or functioning.
Claims (25)
1 . A compound of Formula (A):
or an enantiomer or enantiomerically enriched mixture thereof, or a pharmaceutically acceptable salt, prodrug, hydrate, or solvate of any of the foregoing, wherein:
R 1 is —CH 3 , —CD 3 , or —CF 3 ;
R 2 is —CH 3 , —CD 3 , or —CF 3 ; and
X is —CH 3 , —CD 3 , or —CF 3 ;
provided that when both R 1 and R 2 are —CH 3 , X is —CD 3 or —CF 3 .
2 . The compound of claim 1 , having the structure of Formula (A-1), (A-2), or (A-3):
3 . The compound of claim 1 , having the structure of Formula (A-4), (A-5), or (A-6):
4 . The compound of claim 1 , having the structure of Formula (A-7) or (A-8):
5 . The compound of claim 1 , having the structure of Formula (A-9):
6 . The compound of claim 2 , having the structure of:
7 . The compound of claim 2 , having the structure of:
8 . The compound of claim 2 , having the structure of:
9 . The compound of claim 3 , having the structure of:
10 . The compound of claim 3 , having the structure of:
11 . The compound of claim 3 , having the structure of:
12 . The compound of claim 4 , having the structure of:
13 . The compound of claim 4 , having the structure of:
14 . The compound of claim 5 , having the structure of:
15 . The compound of claim 2 , having the structure of an (R)-enantiomer of Formula (A-1), (A-2), or (A-3):
16 . A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 , and a pharmaceutically acceptable carrier, diluent, or excipient.
17 . The pharmaceutical composition of claim 16 , wherein the composition is in a unit dosage form.
18 . The pharmaceutical composition of claim 17 , wherein the unit dosage form is an immediate release formulation, a modified release formulation, a controlled release formulation, an extended release formulation, a sustained release formulation, or a delayed release formulation.
19 . The pharmaceutical composition of claim 16 , wherein the composition is formulated for oral, buccal, sublingual, inhalation, intranasal, injectable, or transdermal administration.
20 . The pharmaceutical composition of claim 19 , wherein the injectable administration is subcutaneous, intramuscular, or intravenous administration.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 21, 2024
From: DALEY, PAUL F.; COZZI, NICHOLAS V.
To: ALEXANDER SHULGIN RESEARCH INSTITUTE, INC.
Reel/Frame 069364/0163 →
Continuity (2)
Provisional Application
63248450
· Sep 25, 2021
References Cited (182)
US 4327725A
· Cortese et al.
· 1982
[cited by applicant]
US 4624848A
· Lee
· 1986
[cited by applicant]
US 4871549A
· Ueda et al.
· 1989
[cited by applicant]
US 4933504A
· Correale et al.
· 1990
[cited by applicant]
US 4968509A
· Radebaugh et al.
· 1990
[cited by applicant]
US 5011692A
· Fujioka et al.
· 1991
[cited by applicant]
US 5017381A
· Maruyama et al.
· 1991
[cited by applicant]
US 5229135A
· Philippon et al.
· 1993
[cited by applicant]
US 5260068A
· Chen
· 1993
[cited by applicant]
US 5260069A
· Chen
· 1993
[cited by applicant]
US 5456923A
· Nakamichi et al.
· 1995
[cited by applicant]
US 5461140A
· Heller et al.
· 1995
[cited by applicant]
US 5508040A
· Chen
· 1996
[cited by applicant]
US 5516527A
· Curatolo
· 1996
[cited by applicant]
US 5567441A
· Chen
· 1996
[cited by applicant]
US 5622721A
· Dansereau et al.
· 1997
[cited by applicant]
US 5686105A
· Kelm et al.
· 1997
[cited by applicant]
US 5700410A
· Nakamichi et al.
· 1997
[cited by applicant]
US 5837284A
· Mehta et al.
· 1998
[cited by applicant]
US 5840329A
· Bai
· 1998
[cited by applicant]
US 5977175A
· Lin
· 1999
[cited by applicant]
US 6465014B1
· Moroni et al.
· 2002
[cited by applicant]
US 6875751B2
· Imbach et al.
· 2005
[cited by applicant]
US 6932983B1
· Straub et al.
· 2005
[cited by applicant]
US 7585851B2
· Bryant et al.
· 2009
[cited by applicant]
US 7964580B2
· Sofia et al.
· 2011
[cited by applicant]
US 20150367091A1
· Djupesland et al.
· 2015
[cited by applicant]
EP 2007397B1
· 2008
[cited by applicant]
EP 3565550B1
· 2019
[cited by applicant]
WO 2022038170A1
· 2022
[cited by applicant]
WO 2023023351A1
· 2023
[cited by applicant]
Marcher-Rørsted et al., Investigation of the 2,5-Dimethoxy Motif in Phenethylamine Serotonin 2A Receptor Agonists, ACS Chem. Neurosci., 2020, 11, pp. 1238-1244 (Year: 2020).
[cited by examiner]
Harbeson, Deuterium in Drug Discovery and Development, Annual Reports in Medicinal Chemistry, 2011, 46, pp. 403-417 (Year: 2011).
[cited by examiner]
Holze et al. Safety pharmacology of acute LSD administration in healthy subjects [published correction appears in Psychopharmacology (Berl). Feb. 2022;239(2):661]. Psychopharmacology (Berl). 2022;239(6):1893-1905.
[cited by applicant]
Huang RY, et al., Sobologram Analysis: A Comprehensive Review of Methodology and Current Research. Front in Pharmacology, 2019; 10:1222.
[cited by applicant]
Izumi et al. Effects of co-administration of a selective serotonin reuptake inhibitor and monoamine oxidase inhibitors on 5-HT-related behavior in rats. European Journal of Pharmacology. 2006;532(2):258-264.
[cited by applicant]
Jaiswal M, et al., Nanoemulsion: an advanced mode of drug delivery system. Biotech., 2015; 3(5):123-7.
[cited by applicant]
Janssen et al. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015;2015:438403.
[cited by applicant]
Johnson M, Richards W & Griffiths R, Human hallucinogen research: guidelines for safety. J Psychopharmacology, 2008;22: 603-20.
[cited by applicant]
Jovel et al. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J Forensic Sci. 2014;59(3):844-846.
[cited by applicant]
Karlsson. Drugs that induce delirium. Dement Geriatr Cogn Disord. 1999; 10(5):412-415.
[cited by applicant]
Katritzky et al. Preparation of 2-alkoxy-5-methoxybenzaldehydes and 2-ethoxy-5-alkoxybenzaldehydes. ARKIVOC, 2000 (vi), 868-875.
[cited by applicant]
Katz et al. Characterizing the psychological state produced by LSD. J Abnorm Psychol. 1968;73(1):1-14.
[cited by applicant]
Kedrowski Sma, et al., 1-Oxo-5-hydroxytryptamine: A Surprisingly Potent Agonist of the 5-HT3 (Serotonin) Receptor. Organic Letters, 2007; 9(17):3205-7.
[cited by applicant]
Keri RP, et al., An overview of benzo[b]thiophene-based medicinal chemistry. European J Med Chem, 2017; 138:1002-33.
[cited by applicant]
Kim et al. Critical evaluation of human oral bioavailability for pharmaceutical drugs by using various cheminformatics approaches. Pharm Res. 2014;31(4):1002-1014.
[cited by applicant]
Klein et al. Investigation of the Structure-Activity Relationships of Psilocybin Analogues. ACS Pharmacol Transl Sci. 2020;4(2):533-542.
[cited by applicant]
Klein et al. Receptor binding profiles and behavioral pharmacology of ring-substituted N, N-diallyltryptamine analogs. Neuropharmacology. 2018;142:231-239.
[cited by applicant]
Knights et al. In Vitro Drug Metabolism Using Liver Microsomes. Curr Protoc Pharmacol. 2016;74:7.8.1-7.8.24.
[cited by applicant]
Ko JW, et al. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6, Br J Clin Pharmacol, 2000;29(4):343-451.
[cited by applicant]
Kroenke K, et al., The PHQ9: Validity of a brief depression severity measure. Journal of General Internal Medicine. 2001;16(9):606-13.
[cited by applicant]
Kushner DJ, Baker A & Dunstall TG, Pharmacological uses and perspectives of heavy water and deuterated compounds, Can. J. Physiol. Pharmacol. 1999;77:79.
[cited by applicant]
Larock. Comprehensive Organic Transformations: A Guide to Functional Group Preparations. VCH Publishers. 1989.
[cited by applicant]
Leth-Petersen et al. Metabolic Fate of Hallucinogenic NBOMes. Chem Res Toxicol. 2016;29(1):96-100.
[cited by applicant]
Liechti ME et al., Gender Differences in the Subjective Effects of MDMA. Psychopharmacology (Berl) 2001; 154(2):161-8.
[cited by applicant]
Lima et al. Acute kidney injury due to rhabdomyolysis. Saudi J Kidney Dis Transpl. 2008; 19(5):721-729.
[cited by applicant]
Lin T, et al., In vitro assessment of cytochrome P450 inhibition: Strategies for increasing LC/MS based assay throughput using a one point IC50 method and multiplexing high performance liquid chromatograpy. J Pharm Sci.…
[cited by applicant]
Liu & Li. TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg. Front Pharmacol. 2018;9:279.
[cited by applicant]
Lofdahl et al. 5-HT2B receptor antagonists attenuate myofibroblast differentiation and subsequent fibrotic responses in vitro and in vivo. Physiol Rep. 2016;4(15):e12873.
[cited by applicant]
Lopez-Gimenez et al. Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways. Curr Top Behav Neurosci. 2018;36:45-73.
[cited by applicant]
Luethi D & Liechti ME, Designer drugs: mechanism of action and adverse effects, Arch. Toxicol., 2020; 94, 1085-133.
[cited by applicant]
Lukasiewicz et al. Serotonergic Psychedelics in Neural Plasticity. Front Mol Neurosci. 2021; 14:748359.
[cited by applicant]
Luo et al. Normal Reference Intervals of Neutrophil-To-Lymphocyte Ratio, Platelet-To-Lymphocyte Ratio, Lymphocyte-To-Monocyte Ratio, and Systemic Immune Inflammation Index in Healthy Adults: a Large Multi-Center Study f…
[cited by applicant]
Lynch T & Price A, The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects, Am Fam Physician. 2007;76(3):391-6.
[cited by applicant]
Martin et al. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol. 2000;68(3):438-450.
[cited by applicant]
Mas M, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp. Ther 1999;290(1):136-45.
[cited by applicant]
Mitchell J, et al., Reply to: Caution at psychiatry's psychedelic frontier and Challenges with benchmarking of MDMA-assisted psychotherapy. Nat Med. 2021;27(6):1025-33.
[cited by applicant]
Mithoefer MC, et al., A Manual for MDMA-Assisted Therapy in the Treatment of Postraumatic Stress Disorder. 2017 Ver 8.1.
[cited by applicant]
Mithoefer MC, et al., The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pil…
[cited by applicant]
Muller DM & Rentsch KM, Generation of metabolites by an automated online metabolism method using human liver microsomes with subsequent identification by LC-MS(n), and metabolism of 11 cathinones. Anal Bioanal Chem. 201…
[cited by applicant]
Mundt JC, et al., Prediciton of Suicidal Behavior in Clinical Research by Lifetime Suicidal Ideation and Behavior Ascertained by the Electronic Columbia-Suicide Severity Rating Scale. The Journal of Clinical Psychiatry.…
[cited by applicant]
Nakagawasi et al. Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives. Neurotoxicology. 2004;25(1-2):223-232.
[cited by applicant]
Neff KD, The Development and Validation of a Scale to Measure Self-Compassion. Self and Identity. 2003;2(3):223-50.
[cited by applicant]
Nichols DE, et al., 2,3-Dihydrobenzofuran Analogues of Hallucinogenic Phenethylamines. J Med Chem, 1991; 34(1):276-81.
[cited by applicant]
Nichols DE, Psychedelics, Pharmacological Reviews, 2016; 68(2):264-355.
[cited by applicant]
Nichols et al. N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues. ACS Chem Neurosci. 2015;6(7):1165-1175.
[cited by applicant]
Nichols et al. Psychedelics as Medicines: An Emerging New Paradigm. Clin Pharmacol Ther. 2017; 101(2):209-219.
[cited by applicant]
Nuutinen & Panula. Histamine in neurotransmission and brain diseases. Adv Exp Med Biol. 2010;709:95-107.
[cited by applicant]
Oehen P, et al., A Randomized Controlled Pilot Study of MDMA-Assisted Psychotherapy for Treatment of Resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology. 2013:40-52.
[cited by applicant]
Okamoto et al. The role of peripheral 5HT2A and 5HT1A receptors on the orofacial formalin test in rats with persistent temporomandibular joint inflammation. Neuroscience. 2005;130(2):465-474.
[cited by applicant]
PCT/US2022/044771. International Search Report. Jan. 25, 2023.
[cited by applicant]
PCT/US2022/044771. Search Strategy. Dec. 28, 2022.
[cited by applicant]
PCT/US2022/044771. Written Opinion of the International Searching Authority. Jan. 25, 2023.
[cited by applicant]
Adams CE, et al. Contingency Management for Patients with Cooccurring Disorders: Evaluation of a Case Study and Recommendations for Practitioners, Case Reports in Psychiatry, 2012, Article ID 731638.
[cited by applicant]
Adler P, et al. Fluorination of carbonyls with nucleophilic fluorine. Nat. Chem. 2019;11:329-34.
[cited by applicant]
Ahern E, Semkovska M. Cognitive functioning in the first-episode of major depressive disorder: A systematic review and meta-analysis. Neuropsychology. 2017;31(1):52-72.
[cited by applicant]
Azra et al. AAPA PharmaSciTech., 2009;10(1):220-6.
[cited by applicant]
Barry et al. Comparable efficacy of contingency management for cocaine dependence among African American, Hispanic, and White methadone maintenance clients. Psychol Addict Behav. 2009;23(1):168-174.
[cited by applicant]
Berge et al., Pharmaceutical Salts. J.Pharm. Sci., 1977;66:1-19.
[cited by applicant]
Boettger, et al. “Delirium in advanced age and dementia: A prolonged refractory course of delirium and lower functional status.” Palliative & supportive care vol. 13,4 (2015): 1113-21.
[cited by applicant]
Boyer & Shannon. “The serotonin syndrome.” The New England journal of medicine vol. 352, 11 (2005): 1112-20.
[cited by applicant]
Brown, et al. “Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.” Clinical pharmacokinetics 2017;56(12): 1543-1554.
[cited by applicant]
Buysse Dj et al., The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28(2):193-213.
[cited by applicant]
Carter et al. “Drug-Induced Delirium” Drug Safety. 1996;15:291-301.
[cited by applicant]
Casper, et al. Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MSn, and LC-HR-MS/MS. Drug Tes…
[cited by applicant]
Castellanos et al. Chronic pain and psychedelics: a review and proposed mechanism of action. Reg Anesth Pain Med. 2020;45(7):486-494.
[cited by applicant]
Chan et al. Validation of the social functioning scale: Comparison and evaluation in early psychosis, autism spectrum disorder and social anxiety disorder. Psychiatry Res. 2019;276:45-55.
[cited by applicant]
Chan FK, et al., Programmed Necrosis in the Cross Talk of Cell Death and Inflammation, Annu Rev Immunol. 2015;33:79-10.
[cited by applicant]
Chavda VP & Shah D, Micro and Nano Technologies, Nanostructures for Cancer Therapy. Elsivier. 2017:643-718.
[cited by applicant]
Chefer VI, et al., Curr Protoc Neurosci. 2009; Chapter: Unit 7.1.
[cited by applicant]
Chi et al. Neuronal cell death mechanisms in major neurodegenerative diseases, Int J Mol Sci. 2018;19(10):3082.
[cited by applicant]
Cozzi et al. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm (Vienna). 2009; 116(12):1591-159…
[cited by applicant]
Crits-Cristoph P, et al., Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse collaborative cocaine.
[cited by applicant]
Darvesh AS, et al., In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery. Expert Opin Drug Discov. 2011; 6(2): 109-27.
[cited by applicant]
Davis MH. Interpersonal Reactivity Index. 1980.
[cited by applicant]
Dean et al. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. 2013;9(2):172-178.
[cited by applicant]
Dos Santos et al. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. J Psychopharmacol. 2021;35(4):453-458.
[cited by applicant]
Dugger BN & Dickson DW, Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017;9(7):a028035.
[cited by applicant]
Fabbri et al. Measuring Subjective Sleep Quality: A Review. Int J Environ Res Public Health. 2021;18(3):1082.
[cited by applicant]
Flanagan & Nichols. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30(4):363-375.
[cited by applicant]
Flanagan et al. Activation of 5-HT2 Receptors Reduces Inflammation in Vascular Tissue and Cholesterol Levels in High-Fat Diet-Fed Apolipoprotein E Knockout Mice. Sci Rep. 2019;9(1):13444.
[cited by applicant]
Flanagan et al. Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore. ACS Pharmacol Transl Sci. 2020;4(2):488-502.
[cited by applicant]
Foster A, et al., Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design, Adv. Drug Res., 1985;14:1-36.
[cited by applicant]
Frau L, et al., Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain, Neurotoxicology. 2016;56:127-38.
[cited by applicant]
Frau L, et al., Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J. Neurochem., 201…
[cited by applicant]
Gajula et al. Drug metabolic stability in early drug discovery to develop potential lead compounds. Drug Metab Rev. 2021;53(3):459-477.
[cited by applicant]
Germolec et al. Markers of Inflammation. Methods Mol Biol. 2018;1803:57-79.
[cited by applicant]
Gillis EP, et al., Applications of fluorine in medicinal chemistry. J Med Chem. 2015;58(21):8315-59.
[cited by applicant]
Glennon R, Arylalkylamine Drugs of Abuse: An Overview of Drug Discrimination Studies, Pharmacology Biochemistry and Behavior, 1999; 64, 251-56.
[cited by applicant]
Glennon R, et al., 5-HT1 and 5-HT2 binding characteristics of 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane analogs. J Med Chem 1986;29(2):194-9.
[cited by applicant]
Green BL, Trauma History Questionaire. Measurement of stress, self-report trauma, and adaptation. 1996.
[cited by applicant]
Greene TA & Wuts PGM, “Protective Groups in Organic Chemistry,” (Wiley, 2nd ed. 1991).
[cited by applicant]
Grob CS & Grigsby J, Handbook of Medical Hallucinogens, 2021.
[cited by applicant]
Gwaltney et al. Self-efficacy and smoking cessation: a meta-analysis. Psychol Addict Behav. 2009;23(1):56-66.
[cited by applicant]
Halberstadt & Geyer. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology (Berl). 2013;227(4):727-739.
[cited by applicant]
Halberstadt & Geyer. Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology. 2014;77:200-207.
[cited by applicant]
Halberstadt et al. Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice. J Psychopharmacol. 2011;25(11):1548-1561.
[cited by applicant]
Halberstadt et al. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA) [published correction appears in Psychopharmacology (Berl). Nov. 1, 20185;: ]. Psychopharmacology (Berl). 2…
[cited by applicant]
Harris DS, et al. “Subjective and hormonal effects of 3, 4-methylenedioxymethamphetamine (MDMA) in humans.” Psychopharmacology 2002;162:396-405.
[cited by applicant]
Harrison IT & Harrison S, et al., “Compendium of Synthetic Organic Methods,” 1971-1996 vols. 1-8 John Wiley and Sons.
[cited by applicant]
Hawker et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade…
[cited by applicant]
Herndon JM, et al., Glial Cell Response to 3,4-(±)-Methylenedioxymethamphetamine and Its Metabolites, Toxicological Sciences, 2014;138(1):130-8.
[cited by applicant]
Holland J, et al., Ecstasy: The Complete Guide; A Comprehensive Look at The Risks and Benefits of MDMA, 2001;82 n.2.
[cited by applicant]
Pedersen AJ, Petersen Th & Linnet K, In vitro metabolism and pharmacokinetic studies on methylone, Drug Metab Dispos, 2013;41:1247-55.
[cited by applicant]
Pelletier & Siegel. Wishing away inflammation? New links between serotonin and TNF signaling. Mol Interv. 2009;9(6):299-301.
[cited by applicant]
Perez Silanes S, et al., J Heterocyclic Chem, 2001; 38(5):1025-30.
[cited by applicant]
Perona et al. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: prominent effects of dopamine transporter deletions. Behav Pharmacol. 2008; 19(5-6):566-574.
[cited by applicant]
Petry et al. “Prize reinforcement contingency management for cocaine dependence: integration with group therapy in a methadone clinic.” Journal of consulting and clinical psychology. 2005;73(2):354.
[cited by applicant]
Polderman. Acute renal failure and rhabdomyolysis. Int J Artif Organs. 2004;27(12):1030-1033.
[cited by applicant]
Reckweg et al. A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N, N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. Front Pharmacol. 2021;12:760671.
[cited by applicant]
Redfern et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developme…
[cited by applicant]
Revel et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci U S A. 2011;108(20):8485-8490.
[cited by applicant]
Rickli et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015;99:546-553.
[cited by applicant]
Rickli et al. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26(8):1327-1337.
[cited by applicant]
Rogers G, et al., The Harmful Effects of Recreational Ecstacy: A Systematic Review of Observational Evidence. Health Technology Assessment, 2009; 13(6): iii-iv, ix-xii, 1-315.
[cited by applicant]
Salaffi et al. How to measure chronic pain: New concepts. Best Pract Res Clin Rheumatol. 2015;29(1):164-186.
[cited by applicant]
Schenberg EE, Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. Neuropharmacology, 2018;9:733.
[cited by applicant]
Segonzac et al. Tryptamine, a substrate for the serotonin transporter in human platelets, modifies the dissociation kinetics of [3H]imipramine binding: possible allosteric interaction. J Neurochem. 1985;44(2):349-356.
[cited by applicant]
Sheehan DV, et al., The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. 1998.
[cited by applicant]
Shulgin & Shulgin. PiHKAL: A Chemical Love Story, 1992 Transform Press, Berkeley CA.
[cited by applicant]
Shulgin & Shulgin. TiHKAL: The Continuation, 1997 Transform Press.
[cited by applicant]
Simmler et al. In Vitro Characterization of Psychoactive Substances at Rat, Mouse, and Human Trace Amine-Associated Receptor 1. J Pharmacol Exp Ther. 2016;357(1):134-144.
[cited by applicant]
Simmler et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol. 2013;168(2):458-470.
[cited by applicant]
Simplício et al. Prodrugs for Amines, Molecules, 2008;13(3):519-47.
[cited by applicant]
Spitzer RL et al., A Breif Measure for Assessing Generalized Anxiety Disorder: The GAD-7 Archives of Internal Medicine. 2006;166(10):1092-7.
[cited by applicant]
Stotts AL, et al., Motivational Interviewing with Cocaine-Dependent Patients: A Pilot Study, J. Consul. Clin. Psychol. 2001;69(5):858-62.
[cited by applicant]
Szabo & Slavish. Measuring salivary markers of inflammation in health research: A review of methodological considerations and best practices. Psychoneuroendocrinology. 2021;124:105069.
[cited by applicant]
Tadano et al. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain. J Pharmacol Exp Ther. 1989;250(1):254-260.
[cited by applicant]
Taghizadeh G, et al., Protective effects of physical exercise on MDMA-induced cognitive and mitochondrial impairment. Free Radic. Biol. Med. 2016;99:11-9.
[cited by applicant]
Takano H, Cognitive Function and Monoamine Neurotransmission in Schizophrenia: Evidence From Positron Emission Tomography Studies. Front Psychiatry, 2018;9:228.
[cited by applicant]
Tarawneh R, et al., Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease, Neurol. 2015; 72(6):656-65.
[cited by applicant]
Thiehoff C, Rey YP & Gilmour R. The flourine gauche effect: a brief history. Isreal. J. Chem. 2016;57(1-2):92-10.
[cited by applicant]
Toh EA, et al., Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington's disease: a 12-month longitudinal study, Transl Neurodegener. 2014;3:15.
[cited by applicant]
Toro-Sazo et al. 5-HT2 receptor binding, functional activity and selectivity in N-benzyltryptamines. PLoS One. 2019;14(1):e0209804.
[cited by applicant]
Traschel D, Flourine in psychedelic phenethylamines. Drug Testing and Analysis. 2012;4(7-8):577-90.
[cited by applicant]
Tsujikawa K, et al., Urinary excretion profiles of N-hydroxy-3,4-methylenedioxymethamphetamine in rats, Xenobiotica 2011;41(7):578-84.
[cited by applicant]
Uebelhack R & Schewe FH., Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava), Pharmacopsychiatry, 1998;31(5):187-92.
[cited by applicant]
Vig BS, et al., Amino Acids as Promoieties in Prodrug Design and Development. Advanced Drug Delivery Reviews, 2013;65(10):1370-85.
[cited by applicant]
Wang et al. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016;83(11):810-817.
[cited by applicant]
West et al. Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension. PLoS One. 201611(2):e0148657.
[cited by applicant]
Weyler W & Salach Ji, Purification and Properties of Mitochondrial Monoamine Oxidase Type A from Human Placenta, J Biol Chem, 1985; 260(24):13199-207.
[cited by applicant]
Wojcikowsci J, et al., In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: A prediction of possible drug-drug interactions. Pharmacol Rep. 2020;72(3)612-21.
[cited by applicant]
Wong DF & Gjedde A, Monoamines: Human brain imaging, Encyclopedia of Neuroscience, 2009; 939-52.
[cited by applicant]
Woods et al. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br J Pharmacol. 2012;167(2):436-44…
[cited by applicant]
Yamamoto et al. Metabolism of methamphetamine, amphetamine and p-hydroxymethamphetamine by rat-liver microsomal preparations in vitro. Xenobiotica, 1984;14(11)867-75.
[cited by applicant]
Yamashiro T, et al., pH-dependent pyridoxine transport by SLC19A2 and SLC19A3: Implications for absorption in acidic microclimates, J Biol Chem. 2020;295(50):16998-17008.
[cited by applicant]
European Search Report for Applicant's co-pending counterpart EP application EP 22873724.3 with Supplementary Partial European Search Report and Provisional Opinion Accompanying the Partial Search Result.
[cited by applicant]
Gallardo-Godoy et al. Sulfur-substituted alpha-alkyl phenethylamines as selective and reversible MAO-A inhibitors: biological activities, CoMFA analysis, and active site modeling. J Med Chem. 2005;48(7):2407-2419.
[cited by applicant]
Harbeson et al. Deuterium in Drug Discovery and Development. Annual Reports in Medicinal Chemistry. 2011;46:403-417.
[cited by applicant]
Timmins. Deuterated drugs: where are we now? Expert Opinion on Therapeutic Patients. 2014;24(10):29.
[cited by applicant]